Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly Pemetrexed and Radiotherapy in Locally Advanced or Locally Relapsed Non-squamous NSCLC
2012-004223-20Phase 2Active
- Sponsor
- Università Campus Bio-Medico di Roma
- Start
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed in Non-small cell lung cancer (NS-NSCLC), sponsored by Università Campus Bio-Medico di Roma. Primary endpoint: Maximum tolerated dose of weekly pemetrexed with concurrent radiotherapy. Started Sep 2012; status: active.
02
Drugs
pemetrexed
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on 2012-004223-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004223-20.